Citations

Showing 10 of 108083 citations.

Exercise-Echocardiography-Derived Pulmonary Artery Pressure Slope in Borderline and Mild to Moderate Pulmonary Arterial Hypertension
Ammash, Naser M., McGoon, Michael D., Shub, Clarence, Seward, James B., Oh, Jae K. , Krowka, Michael J. , Moon, Brenda S., Bailey, Kent R. , Wood, Christina M., Tajik, A. Jamil , Pellikka, Patricia A.

Mayo Clinic

Clinical medicine. Cardiology | September 20, 2017 | Volume: 2 | Issue: No issue available | Pages: CMC.S740

10.4137/cmc.s740 Get It

Measurement with a wink
Kunneman, Marleen , Montori, Víctor M. , Shah, Nilay D. , Montori, Victor M

Mayo Clinic

BMJ Quality & Safety | September 20, 2017 | Volume: 26 | Issue: 10 | Pages: 849-851

10.1136/bmjqs-2017-006814 | PMID 28733369 Get It

Zeroing out preventable disability: Daring to dream the impossible dream for dementia care
Khachaturian, Ara S. , Frank, Lori , Petersen, Ronald C. , Carson, Brad R., Khachaturian, Zaven S., Hoffman, David P.

Mayo Clinic

Alzheimer's & Dementia | September 19, 2017 | Volume: 13 | Issue: 10 | Pages: 1077-1080

10.1016/j.jalz.2017.09.003 | PMID 28935202 Get It

Amyloid-Beta-Related Angiitis with Distinctive Neuro-Ophthalmologic Features
Dumitrașcu, Oana , Okazaki, Erin, Cobb, Steven H., Zarka, Matthew A., Souza, Stephen De , Kumar, Gyanendra , O’Carroll, Cumara B. , Dumitrascu, Oana M , Okazaki, Erin M

Mayo Clinic

Neuro-Ophthalmology | September 19, 2017 | Volume: 42 | Issue: 4 | Pages: 237-241

10.1080/01658107.2017.1374982 | PMID 30042795 Get It

Early genetic aberrations in patients with sporadic colorectal cancer
Druliner, Brooke R. , Ruan, Xiaoyang , Sicotte, Hugues , O’Brien, Daniel R. , Kocher, Jean‐Pierre , Boardman, Lisa A. , Boardman, Lisa , Liu, Hongfang

Mayo Clinic

Molecular Carcinogenesis | September 19, 2017 | Volume: 57 | Issue: 1 | Pages: 114-124

10.1002/mc.22738 | PMID 28926134 Get It

Chromosome instability (CIN) is widely observed in both sporadic and hereditary colorectal cancer (CRC). Defects in APC and WNT signaling are primarily associated with CIN in hereditary CRC, but the genetic causes for CIN in sporadic CRC remain elusive. Using high‐density SNP array and exome data from The Cancer Genome Atlas (TCGA), we characterized loss of heterozygosity (LOH) and copy number variation (CNV) in the peripheral blood, normal colon, and corresponding tumor tissue in 15 CRC patients with proficient mismatch repair (MMR) and 24 CRC patients with deficient MMR. We found a high frequency of 18q LOH in tumors and arm‐specific enrichment of genetic aberrations on 18q in the normal colon (primarily copy neutral LOH) and blood (primarily copy gain). These aberrations were specific to the sporadic, pMMR CRC. Though in tumor samples genetic aberrations were observed for genes commonly mutated in hereditary CRC (eg, APC, CTNNB1, SMAD4, BRAF), none of them showed LOH or CNV in the normal colon or blood. DCC located on 18q21.1 topped the list of genes with genetic aberrations in the tumor. In an independent cohort of 13 patients subjected to Whole Genome Sequencing (WGS), we found LOH and CNV on 18q in adenomatous polyp and tumor tissues. Our data suggests that patients with sporadic CRC may have genetic aberrations preferentially enriched on 18q in their blood, normal colon epithelium, and non‐malignant polyp lesions that may prove useful as a clinical marker for sporadic CRC detection and risk assessment.
A CRISPR reimagining: New twists and turns of CRISPR beyond the genome‐engineering revolution
Plummer, Robert J., Guo, Yi , Peng, Ying , Plummer, Robert J.

Mayo Clinic

Journal of Cellular Biochemistry | September 19, 2017 | Volume: 119 | Issue: 2 | Pages: 1299-1308

10.1002/jcb.26406 | PMID 28926145 Get It

AbstractDespite its explosive applications in genome engineering, CRISPR (Clustered Regularly Interspersed Short Palindromic Repeats) has been developed into a versatile tool beyond its well‐known nuclease function. In this prospect article, we summarize a few exciting “off‐label” applications of CRISPR including manipulating DNA sequences, visualizing chromosomal loci in living cells, and modulating transcription and chromatin structures. These novel applications will likely elevate CRISPR tools into yet another level of sophistication and diversity, leading to many more exciting cell biological discoveries.
Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma
Chang, Xiu-Bao, Xu, Qinqin , Hou, Yuexian, Li, Cynthia , Stewart, A. Keith, Chang, Xiubao, Xu, Ye, Chang, Xiu-Bao, Xu, Ye

Mayo Clinic

International Journal of Molecular Sciences | September 19, 2017 | Volume: 18 | Issue: 9 | Pages: 1999

10.3390/ijms18091999 | PMID 28926977 Get It

Immunomodulatory drugs (IMiDs) are profoundly active compounds in the treatment of patients with multiple myeloma (MM). However, despite the fact that treatment with IMiDs has dramatically improved survival for patients with MM, the majority of MM patients develop IMiDs resistance over time. We have found that expression of functional cereblon is required for IMiDs′ action. In addition, it has been reported that cells expressing high levels of cereblon are resistant to proteasome inhibitor, implying that patients with high levels of cereblon should be resistant to proteasome inhibitor. If the above conclusions are correct, cereblon could be considered as a biomarker to determine which standard regimens should be used to treat patients with MM. Unfortunately, the conclusions mentioned above have not been clinically confirmed. In order to confirm these conclusions, we have generated three highly specific mouse monoclonal antibodies (mAbs) against full-length human cereblon. These mAbs can be used to do western blot, immunoprecipitation and immunohistochemistry staining. In addition, their epitopes have been precisely determined and the peptides covering their epitopes completely blocked the antibody binding to cereblon in western blot analysis or in immunohistochemistry staining of MM patients′ specimens.
Quantification of Etoposide Hypersensitivity: A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality
Secreto, Frank J., Smith, Alyson , Bruinsma, Elizabeth S. , Perales‐Clemente, Ester , Oommen, Saji , Hawse, Gresin, Hrstka, Sybil , Arendt, Bonnie K., Brandt, Emma B. , Wigle, Dennis A. , Smith, Alyson J, Perales-Clemente, Ester, Hrstka, Sybil C L, Nelson, Timothy J , Li, Xing , Hawse, Gresin P. , Nelson, Timothy J. , Hrstka, Sybil C

Mayo Clinic

Stem Cells Translational Medicine | September 19, 2017 | Volume: 6 | Issue: 10 | Pages: 1829-1839

10.1002/sctm.17-0116 | PMID 28924979 Get It

Abstract Human induced pluripotent stem cells (hiPSC) hold great promise in diagnostic and therapeutic applications. However, translation of hiPSC technology depends upon a means of assessing hiPSC quality that is quantitative, high-throughput, and can decipher malignant teratocarcinoma clones from normal cell lines. These attributes are lacking in current approaches such as detection of cell surface makers, RNA profiling, and/or teratoma formation assays. The latter remains the gold standard for assessing clone quality in hiPSCs, but is expensive, time-consuming, and incompatible with high-throughput platforms. Herein, we describe a novel method for determining hiPSC quality that exploits pluripotent cells’ documented hypersensitivity to the topoisomerase inhibitor etoposide (CAS No. 33419-42-0). Based on a study of 115 unique hiPSC clones, we established that a half maximal effective concentration (EC50) value of <300 nM following 24 hours of exposure to etoposide demonstrated a positive correlation with RNA profiles and colony morphology metrics associated with high quality hiPSC clones. Moreover, our etoposide sensitivity assay (ESA) detected differences associated with culture maintenance, and successfully distinguished malignant from normal pluripotent clones independent of cellular morphology. Overall, the ESA provides a simple, straightforward method to establish hiPSC quality in a quantitative and functional assay capable of being incorporated into a generalized method for establishing a quality control standard for all types of pluripotent stem cells.
Association of genetic variants with fatigue in patients with malignant glioma
Armstrong, Terri S. , Vera, Elizabeth , Zhou, Renke, Acquaye, Alvina , Sullaway, Catherine, Berger, Ann M. , Mahajan, Anita , Bondy, Melissa L. , Scheurer, Michael E. , Armstrong, Terri S , Breton, Ghislaı̀n , Wefel, Jeffrey S. , Gilbert, Mark R.

Mayo Clinic

Neuro-Oncology Practice | September 19, 2017 | Volume: 5 | Issue: 2 | Pages: 122-128

10.1093/nop/npx020 | PMID 31386001 Get It

AbstractBackgroundFatigue is a consistently reported, severe symptom among patients with gliomas throughout the disease trajectory. Genomic pathways associated with fatigue in glioma patients have yet to be identified.MethodsClinical factors (performance status, tumor details, age, gender) were collected by chart review on glioma patients with fatigue (“I have lack of energy” on Functional Assessment of Cancer Therapy-Brain), as well as available genotyping data. Candidate genes in clock and inflammatory pathways were identified from a literature review, of which 50 single nucleotide polymorphisms (SNPs) in 7 genes were available. Clinical factors and SNPs identified by univariate analyses were included in a multivariate model for moderate-severe fatigue.ResultsThe study included 176 patients (median age = 47 years, 67% males). Moderate-severe fatigue was reported by 43%. Results from multivariate analysis revealed poor performance status and 2 SNPs were associated with fatigue severity. Moderate-severe fatigue was more common in patients with poor performance status (OR = 3.52, P < .01). For each additional copy of the minor allele in rs934945 (PER2) the odds of fatigue decreased (OR = 0.51, P < .05). For each additional copy of the minor allele in rs922270 (ARTNL2) the odds of fatigue increased (OR = 2.38, P < .01). Both of these genes are important in the circadian clock pathway, which has been implicated in diurnal preference, and duration and quality of sleep. No genes in the inflammatory pathway were associated with fatigue in the current study.ConclusionsIdentifying patients at highest risk for fatigue during treatment allows for improved clinical monitoring and enrichment of patient selection for clinical trials.
Response to “Re: ‘Snare-Ride: A Bailout Technique to Catheterize Target Vessels With Unfriendly Anatomy in Branched Endovascular Aortic Repair’”
Ferreira, Marcelo , Katsargyris, Αthanasios , Rodrigues, Eduardo, Ferreira, Diego, Cunha, Rodrigo, Bicalho, Guilherme , Verhoeven, Eric L.G. , Oderich, Gustavo, Rodrigues, Eduardo, Oderich, Gustavo S.

Mayo Clinic

Journal of Endovascular Therapy | September 19, 2017 | Volume: 24 | Issue: 5 | Pages: 752-752

10.1177/1526602817729278 | PMID 28925335 Get It